Search Results
Apr 17, 2026, 15:00 ET Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
including Agilent Technologies.In a study conducted with Agilent Technologies and Ajou University Medical Center, researchers used Lunit SCOPE IO and uIHC to analyze over 25,000 non-small cell lung cancer (NSCLC) samples. The results showed that tumors with high c-MET expression exhibited a significant
More news about: Lunit
Dec 15, 2025, 09:00 ET Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programsSEOUL, South Korea, Dec. 15, 2025 /PRNewswire/
More news about: Lunit
Nov 07, 2025, 09:05 ET Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025
taking place November 5-9 in Maryland, U.S. The findings highlight how Lunit's AI-powered digital pathology technologies—Lunit SCOPE IO® and Lunit SCOPE® uIHC—can advance precision oncology by uncovering predictive immune signatures and guiding antibody-based drug development.
More news about: Lunit
Sep 24, 2025, 09:00 ET Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
immune phenotypes from H&E whole slide images. The Lunit SCOPE suite includes AI-powered tools such as SCOPE IO, SCOPE PD-L1, and SCOPE uIHC. Several of the world's largest pharmaceutical companies have already published their use of these solutions in research settings to support biomarker-driven
More news about: Lunit